Skip to content
Anokion Mobile Menu Toggle navigation
Anokion
  • About Us
    • Overview
    • Board of Directors
  • Science & Platform
    • What is Immune Tolerance?
    • Our Approach
  • Pipeline
    • Overview
    • SynCeD
    • ACeD-it | Celiac Disease
    • ACeD | Celiac Disease
    • MoveS-it | Multiple Sclerosis
  • Investors & Media
    • Overview
    • Press Releases
    • Publications
    • In the News
  • Careers
  • Contact
  • About Us
    • Overview
    • Board of Directors
  • Science & Platform
    • What is Immune Tolerance?
    • Our Approach
  • Pipeline
    • Overview
    • SynCeD
    • ACeD-it | Celiac Disease
    • ACeD | Celiac Disease
    • MoveS-it | Multiple Sclerosis
  • Investors & Media
    • Overview
    • Press Releases
    • Publications
    • In the News
  • Careers
  • Contact
  • Terms of Use
  • Privacy: US
  • Privacy: EU/UK
  • Site Credits

Anokion Presents New Data Describing Transformative Therapeutic Approach for Treatment of Multiple Sclerosis at ECTRIMS Congress

Post navigation

Erythrocyte-driven ‘memory of tolerance’ demonstrated in recent journal publication
Article Published in The Lancet Gastroenterology & Hepatology Highlighting Safety and Preliminary Effects of KAN-101 in Celiac Disease in its ACeD Phase 1 Clinical Trial

Recent Comments

    Archives

    Categories

    • No categories

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Anokion
    • +1 857.320.6607
    • info@anokion.com
    • LinkedIn

    © 2025

    • Terms of Use
    • Privacy: US
    • Privacy: EU/UK
    • Site Credits

    © 2025